Compare VYX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | NBTX |
|---|---|---|
| Founded | 1881 | 2003 |
| Country | United States | France |
| Employees | 13500 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.9M | 1.0B |
| IPO Year | N/A | 2018 |
| Metric | VYX | NBTX |
|---|---|---|
| Price | $8.39 | $45.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $13.67 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 2.1M | 56.8K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.02 | $3.64 |
| 52 Week High | $14.67 | $44.46 |
| Indicator | VYX | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.59 | 72.20 |
| Support Level | $6.04 | $20.11 |
| Resistance Level | $10.24 | N/A |
| Average True Range (ATR) | 0.35 | 2.08 |
| MACD | 0.16 | 1.20 |
| Stochastic Oscillator | 87.05 | 99.80 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.